DNA-based Vaccine Successfully Eradicates Nearly Half of Precancerous Cervical Lesions in Clinical Trial
September 30, 2015
Using a novel synthetic platform for creating vaccines originally developed in the laboratory of David Weiner, PhD, a team led by his colleagues at the Johns Hopkins University School of Medicine has successfully eradicated precancerous cervical lesions in nearly half of the women who received the investigational vaccine in a clinical trial. The goal, say the scientists, was to find nonsurgical ways to treat precancerous lesions caused by human papillomavirus (HPV).
Read more in the Department of Communications news release.